Navigation Links
Curemark Enters into Research Collaboration with The Molecular Sciences Institute (VTT/MSI)

RYE, N.Y., Aug. 26, 2013 /PRNewswire/ -- Curemark, a drug research and development company focused on neurological disorders, announced today that it has entered into a collaborative research agreement with the VTT/MSI Molecular Sciences Institute (MSI) in Berkeley, CA.

Founded in 1996 by Nobel-prize winner Sydney Brenner, MSI is an independent, not-for-profit research institute. In 2011, MSI created a partnership in bioengineering with VTT (Technical Research Centre of Finland) that is now known as the VTT/MSI Molecular Sciences Institute. VTT/MSI's Center for Bioengineering strives to contribute to the understanding of biology to improve human health and positively impact society.

Curemark's Chief Scientific Officer Dr. Matthew Heil said, "Tapping into MSI's expertise will deepen our knowledge of the full nature of our proprietary enzyme's biological properties.  We expect this research will lead to multiple additional indications and formulation possibilities, which will benefit people with unmet medical needs."

Dr. Orna Resnekov, VTT/MSI Director, echoed Dr. Heil's sentiments. "We are excited to work with Curemark, the leader in novel therapies for autism, to advance the company's exciting research and development program," she said.

Curemark is currently developing a treatment for autism, CM-AT, which the U.S. Food and Drug Administration (FDA) has granted its Fast Track designation.  The FDA Fast Track program facilitates the development and expedites the review of new drugs that are intended to treat serious or life-threatening conditions, and that demonstrate the potential to meet unmet medical needs.

Curemark previously announced successful preliminary discussions with the FDA regarding the anticipated future filing of the company's New Drug Application (NDA) for CM-AT.

About Curemark LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about the company's innovative science, visit

Safe-Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Curemark Awarded New Patent For Treatment Of Drug And Alcohol Addiction
2. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
3. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
4. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
5. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
6. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
7. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
8. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award
9. Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies
10. Eqalix Enters Sponsored Research Agreement with Temple University
11. BCA Represents Independent Blood Centers at Phacilitate Cell & Gene Therapy Forum
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... 24, 2015  Asia-Pacific (APAC) holds the third-largest ... market. The trend of outsourcing to low-cost locations ... higher volume share for the region in the ... margins in the CRO industry will improve. ... ( ), finds that the market earned ...
(Date:11/24/2015)... ... 2015 , ... Copper is an essential micronutrient that all ... copper is also toxic to cells. With a $1.3 million award from the ... a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), a ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... announced a partnership with 2XU, a global leader ... deliver a smart hat with advanced bio-sensing technology. ... other athletes to monitor key biometrics to improve ... strategic partnership, the two companies will bring together the ...
(Date:10/27/2015)... 2015 Munich, Germany ... technology (ASGM) automatically maps data from mobile eye tracking ... , so that they can be quantitatively analyzed with ... Munich, Germany , October 28-29, 2015. SMI,s Automated ... mobile eye tracking videos created with SMI,s Eye ...
(Date:10/26/2015)... , October 26, 2015 ... --> adds Biometrics Market ... 2021 as well as Emerging Biometrics ... reports to its collection of IT ... . --> ...
Breaking Biology News(10 mins):